
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc is poised for significant growth due to its focus on developing MasterKey therapies that target oncogenic mutations, particularly with promising compounds BDTX-4933 and BDTX-1535. The company anticipates achieving a favorable Overall Response Rate (ORR) in the second half of 2025, which could translate into forecasted sales of approximately $500 to $750 million, indicating strong revenue potential. Furthermore, M&A proxy valuations for similar oncology acquisitions suggest a prospective upside of 3 to 6 times from current levels, further enhancing the company's appeal to investors.
Bears say
Black Diamond Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from potential underdosing issues with its therapeutics, which could hinder efficacy outcomes. Additionally, concerns regarding the Phase 3 trial's enrollment of a representative patient population raise the risk of reduced efficacy, particularly for its candidate therapies, BDTX-4933 and BDTX-1535. Furthermore, the company faces multiple threats including disappointing safety and efficacy results, potential delays in research and development, increased competition in its target market, and difficulties in securing adequate funding for ongoing projects.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares